- Solid Tumors
- Pipeline Molecules
- Alliance Partners
Our mission is to provide healthcare professionals with unbiased clinical research information, easily.
Currently, you can access the following clinical trials being conducted worldwide:
Clinicaltrials.gov identifier NCT03936491
Recruitment Status Not yet recruiting
First Posted May 3, 2019
Last update posted May 3, 2019
1. To identify the difference in the lipidomic profiles between ADHD and controls; 2. To examine the effects of methylphenidate and atomoxetine on the lipidomic profiles in ADHD, and the relationship between medication-related changes in the lipidomic profiles and medication-related improvements in the behavioral symptoms and neuropsychological functions; 3. To map medication-related lipidomic biomolecules to their respective metabolic pathways to identify the underlying mechanisms of neuroprotective effects of methylphenidate and atomoxetine.
Background: Although the efficacy of methylphenidate and atomoxetine in ADHD is well documented in clinical trials, more studies are needed to clarify the neuroprotective effects of these two medications. Lipids exert important neuroprotective effects for optimal brain development and functioning. Previous studies have demonstrated the significant connection between lipid dysregulation and the occurrence of ADHD. In addition, lipid dysregulation is closely related to the abnormal neural activity in individuals with ADHD. In this 3-year prospective project, we will perform a lipidomic analysis of blood before and after treatment with methylphenidate or atomoxetine, in order to identify the biological connections between the neuroprotective effects of medications and pathways of lipid metabolism in children with ADHD. Subjects and Methods: 70 drug-naïve patients with ADHD, aged 6-18, and 35 matched typically developing controls will be recruited in this project. We will randomly assign the 70 ADHD patients to two groups, 35 in the methylphenidate group and 35 in the atomoxetine group. Within the 12-week treatment period, we will use ADHDRS-IV, SNAP-IV, CBCL, YSR, CGI-ADHD-S, CGI-ADHD-I, SAICA, and Family APGAR-C to assess the improvement in the behavioral symptoms, and CPT and CANTAB to assess the improvement in the neuropsychological functioning. The blood sample will be collected, and we will use mass spectrometry to assess the medication-related change in lipidomic profiles. Anticipated Results: Using a prospective design, we anticipate that this study will delineate the effects of methylphenidate and atomoxetine on the lipidomic profiles in patients with ADHD. Furthermore, we will conduct pathway analysis to obtain crucial insight to the lipidomic regulation in neurophysiology of children with ADHD. We expect that the findings will increase our understanding of the neuroprotective effects of methylphenidate and atomoxetine in patients with ADHD, and identify the psychopharmacological mechanism of medication effects in ADHD via the pathways of lipid metabolism and regulation.
The subjects will receive methylphenidate according to their clinical symptoms
Methylphenidate is a central nervous system stimulant used for the therapy of attention deficit disorder and narcolepsy.
|Active Comparator: Atomoxetine
The subjects will receive atomoxetine according to their clinical symptoms
Atomoxetine is a medication used to treat attention deficit hyperactivity disorder (ADHD). Use is only recommended in those who are at least six years old. It is taken by mouth.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, , Learn About Clinical Studies.-->
Subjects will be recruited in the present project if they meet the following inclusion
1. Children or adolescents, between 6 and 18 years of age, must have ADHD based on the
diagnostic criteria of the Diagnostic and Statistical Manual of Mental disorders, 5th
2. Their scores of Clinical Global Impressions-ADHD-Severity (CGI-ADHD-S) is greater than
4 at baseline.
3. They have to be medication-naïve. They never receive any medication for the treatment
4. They and their parents must understand sufficiently to communicate properly with the
5. They must have a Full-Scale Intelligence Quotient (FIQ) score greater than 80.
6. They must keep regular clinic visits and all required tests, including collection of
blood sample and neuropsychological testing.
Contact: Chi-Yung Shang 02-23123456 ext 66965 firstname.lastname@example.org
National Taiwan University Hospital
National Taiwan University Hospital
Principal Investigator: Chi-Yung Shang Shang, MDPHD Dept of Psychiatry, National Taiwan University Hospital